<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542552</url>
  </required_header>
  <id_info>
    <org_study_id>ONIMS</org_study_id>
    <nct_id>NCT03542552</nct_id>
  </id_info>
  <brief_title>Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa</brief_title>
  <official_title>Oral Nifedipine Versus Intravenous Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa: Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antepartum hemorrhage is defined as bleeding from or within the female genital tract,
      occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of
      pregnancies and is an important cause of perinatal and maternal morbidity and mortality
      worldwide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are many tocolytic agents may have a role in conservative management of placenta previa
      such as magnesium sulfate, calcium channel blockers and Î²-sympathormimetics. In 2004 Sharma
      suggests that ritodrine hydrochloride in patients with symptomatic placenta previa tends to
      prolong the pregnancy and result in an increase in birth weight of the babies without causing
      any adverse effect on the mother and fetus
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of prolongation of gestation</measure>
    <time_frame>1 month</time_frame>
    <description>measured from the time of enrollment to the time of delivery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Placenta Previa</condition>
  <arm_group>
    <arm_group_label>Nifidipne</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnisum sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion</description>
    <arm_group_label>Magnisum sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours</description>
    <arm_group_label>Nifidipne</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated gestational age : between 28 weeks and 37 week's gestation

          -  Confirmed Placenta previa; either major or minor degrees.

          -  Placenta previa with preterm uterine contractions

        Exclusion Criteria:

          -  Severe attack of bleeding requiring an immediate intervention.

          -  Fetal heart rates instability or non-reassuring tracing

          -  Intrauterine fetal death or major fetal anomalies.

          -  If associated with abruptio placentae

          -  Patients with known bleeding disorders or on anticoagulant therapy

          -  Patients with severe medical disorders as myasthenia gravis documented magnesium
             toxicity.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 19, 2018</last_update_submitted>
  <last_update_submitted_qc>May 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>ramy nasser</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

